Single Best Ideas

Stifel Raises $INBX target from $300 to $325 on recent positive trial data.

@d_esposito37712 We did at $103! You can't control the market - but you can take advantage of good things on sale!

@SingleBestIdeas You get to buy at 106!

HUGE Phase 2 result for $INBX drug that turbocharges performance of Keytruda (pembrolizumab) - $MRK's biggest drug going off patent in 2028. $2B market cap provides plenty of upside as $INBX advances development prnewswire.com/news-releases/…

Kudos to @j16425646 for ferreting out this article on rising use of electronic monitoring for domestic violence applications in Europe. $SPCB asiae.co.kr/en/article/wor… via @asiabus_daily

@Nesjamag @Phoenix_FFM @Aksel465 That's our understanding, along with customer confidentiality provisions, thought sometimes the procurement is public

@Phoenix_FFM @SingleBestIdeas @Aksel465 Competitive reasons I suspect.

SuperCom $SPCB Wins 4 New Electronic Monitoring Contracts in New York, Displacing Incumbent Vendors in 3 and 1 new Program Launch Brings SuperCom's US market wins to over 40 since entering market in mid-2024 prnewswire.com/news-releases/…

@j16425646 Love the story and your enthusiasm - but the Swedish contract that could be worth up to $76M is over a 9 year period - so I don't think $76M + $21M lets you add $50M to 2026!! $SPCB's credibility is already low - so lets stick to the facts - which are already very good!

(3/3) This implies ~$50 million of revenue for $SPCB is already locked in for 2026 (up ~100% YoY), excluding new contracts. SuperCom has become a growth stock priced at <2X '26 EBITDA. It belongs at 20+X. ted.europa.eu/en/notice/-/de…

(1/3) The $SPCB story is much better than I anticipated, and I believed the stock was worth $100+. It seems the company's $55.9mn backlog, may be at least $73 million too low.

Solid report by $SPCB despite the noise of some charges and a material financial gain that impacts reported EPS Call today at 10:00 am prnewswire.com/news-releases/…

@InvestSpecial @HalvioCapital Wow - looks cheap and like it could say that way for years... looking at past few years posts on the name. What's the catalyst to change the valuation?

Got a stock for the obscure, illiquid, nanocap lovers. $FP.V trading at <2x look-through EBITDA - HQ asset worth double current market cap - Net cash balance - Despite newspaper industry headwinds, company remains profitable Pitch by @HalvioCapital

Trump reclassification of Marijuana has to be good for pot stocks? Right? $MSOS

$FTAI is a GREAT co that has been acting like💩recently Smart investor got us in in the teens a few years ago & story keeps getting better as jet engines require maintenance. Guessing weakness relates to fuel price impacts on travel & possible near-term slowing of maintenance?

@DheerajNam We aren't chartists either - but the chart does show it has traded higher and the fundamentals seem to be improving.

Not a chartist but I like the fundamentals $SPCB

@test8612 $SPCB - seems it could easily sell for 20x trailing EPS of $0.80 (our guess) they have $0.70 of untaxed EPS (excluding financial gains) for the 9Months. Q4 report coming by April 30th. So that's $16 - and if they can restore some credibility with investors - even higher!

@SingleBestIdeas How high can it go do you think?

$SPCB 2-year chart suggests there's more to go on the upside as we await year-end results due April 30th. A quick look at the 5-year chart helps explain why impressive electronic monitoring contract wins and rev ramp have been largely ignored ... so far.

$NMAX has been rebounding nicely - making us feel better about violating the falling knives rule in averaging down. LT story seems very compelling as they work to raise their affiliate fees which are well below average

Nice to see $VNCE re-rated following a strong report and $0.44 in TTM eps. Outlook remains excellent!

Nice Q4 & 2025 report from specialty retailer Vince Holdings $VNCE trading $3.12/share; 7x 2025 EPS of $0.44 for a $37.5M mkt cap Veteran retail analyst Eric Beder @SCC_Research raised '26 estimate to $0.55 & PT to $7 or 10x his FY'27 EPS estimate of $0.66

What are we missing in @NEWSMAX $NMAX? 4th most watched cable news network; $131M in cash/equivalents & no debt; Affiliate fee Rev's of 7 cents per MVPD subscriber (monthly) vs. peers ranging from 40 cents - $2 - suggesting upside? Excerpt from @NobleCapMkts report below.

@varunv_malhotra Great write-up - we share his views on $CROX and will take a look at $PDD! Thank you!

The only outside investor Munger trusted with his family's money made 2 new buys in all of 2025. One was a stock he'd sold 4 years earlier. At a higher price. The other was a foam clog company at 6x earnings. His name is Li Lu. Here's what he swung at. (1) $PDD. Q2 2025. What most investors see: a Chinese e-commerce company with declining profits and a Temu brand facing tariffs. Easy pass. What Li Lu sees: PDD built something nobody else has. Direct connections to millions of small farmers and manufacturers in China. No middlemen. No warehouses full of inventory they own. The suppliers bear the risk. PDD is the platform. He first bought in Q4 2020. Sold in Q4 2021. Then Temu launched and took that entire supplier infrastructure global. 80+ countries. The domestic engine that Alibaba and JD couldn't displace is now the backend for the fastest-growing E-commerce app on earth. Different business. Same ticker. The margin of safety: You're buying the dominant agricultural and value commerce platform in China at roughly 10x earnings. $59 billion in cash. 42% of the market cap is just cash sitting on the balance sheet. Subtract it and you're paying about 6x for the operating business. Temu is an expensive bet PDD can afford to make. $59 billion in cash buys you a lot of patience. If it works, you own the infrastructure layer for global value commerce. If it doesn't, you still own Pinduoduo. Which prints cash. (2) $CROX. Q4 2025. What most investors see: Foam clogs. A fad that should have died. What Li Lu sees: A brand that survived being a global punchline and came out stronger. Crocs didn't just survive. They turned mockery into identity. The personalization ecosystem. Jibbitz charms that turn a one-time shoe purchase into repeat spend. Kids collect them. Adults customize them. $5-$8 charms on a product that costs almost nothing to make. That's a razor and blade model hiding inside a footwear company. 58% gross margins because the core product is injection-molded foam. Almost no raw material cost. Almost no fashion risk because the silhouette never changes. The clog is the platform. Everything else is a variant. $659 million in free cash flow. They used it to buy back 10% of their own shares last year. International growing double digits. China up 30%. The Crocs brand grew for the 8th straight year. So why is it this cheap? HEYDUDE. They paid $2.5 billion to acquire it in 2022, loaded up $1.2 billion in debt, and the brand hasn't delivered. Revenue down 14%. That acquisition is the reason you're getting a cash flow machine at 6x earnings. The HEYDUDE disaster is creating the opportunity. The margin of safety: $12.51 EPS on an $80 stock. 6.4x earnings. Even if HEYDUDE goes to zero and you write off the entire brand, the Crocs brand alone did $3.3 billion in revenue at 61% gross margins. Li Lu bought knowing the HEYDUDE mess. He's buying the core Crocs business and treating HEYDUDE as an option that might recover. If CROX drops into the low $70s, watch the next filing. The pattern: Q1: nothing. Q2: $PDD. Q3: nothing. Q4: $CROX. Two swings in four quarters. The rest was silence. Buffett's favorite analogy, one Li Lu has cited: "Ted Williams divided the strike zone into 77 cells. He would insist on swinging only at balls in his best cells, even at the risk of striking out." Most investors think the hard part is finding the right stock. Li Lu's 13F says the hard part is doing nothing the rest of the time.